Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -2.19%68 Pretax Margin % is 13.27% as of Mar. 2026, which is 1% below its 10-year median of 13.37. GuruFocus rates BSP:OFSA3 with a GF Score™ of 68/100 and a GF Value™ of R$26.86 (Fairly Valued). The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Ourofino ranks better than 79.71% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Ourofino's Pre-Tax Income for the
three
months ended in Mar. 2026 was R$33 Mil. Ourofino's Revenue for the
three
months ended in Mar. 2026 was R$250 Mil. Therefore, Ourofino's pretax margin for the quarter that ended in Mar. 2026 was 13.27%.
The historical rank and industry rank for Ourofino's Pretax Margin % or its related term are showing as below:
BSP:OFSA3'
s Pretax Margin % Range Over the Past 10 Years
Min: -2.92 Med: 13.37 Max: 19.28
Current: 19.28
BSP:OFSA3's Pretax Margin % is ranked better than 79.71% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BSP:OFSA3: 19.28
Ourofino (BSP:OFSA3) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ourofino Pretax Margin % Related Terms
Ourofino Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Ourofino's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:OFSA3 vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ourofino's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino (BSP:OFSA3) has a Pretax Margin % of 13.27% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ourofino and its competitors. This is near median its historical median of 13.37. According to the industry distribution chart, Ourofino ranks #195 out of 961 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Ourofino's Pretax Margin % too high?
Ourofino's current Pretax Margin % of 13.27% is near median its 10-year median of 13.37. The Drug Manufacturers industry median Pretax Margin % is 7.28. Ourofino's value of 13.27% is 82.3% above this industry median. Based on the distribution chart, Ourofino ranks #195 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ourofino has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #195 out of 961 companies for Pretax Margin %. This places Ourofino in the top 20% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Ourofino's value of 13.27% is 82.3% above this benchmark. While the company's 10-year median is 13.37 vs. the industry median of 7.28, Ourofino has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current Pretax Margin % of 13.27% is 82.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ourofino and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current Pretax Margin % is 13.27%, which is near median its own 10-year median of 13.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.86, compared to a current price of R$26.80 — trading 0.2% below its estimated fair value. The current Pretax Margin % is 13.27%, which is near median its 10-year median of 13.37 and 82.3% above the Drug Manufacturers industry median of 7.28. Ourofino's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current Pretax Margin % is 13.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$26.80 is trading 0.2% below its estimated GF Value™ of R$26.86.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
Pretax Margin %: 13.27% (near median its 10-year median of 13.37)
GF Value™: R$26.86 vs. price of R$26.80 (0.2% below fair value)
Industry Position: 82.3% above the Drug Manufacturers median (#195 of 961)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
68GF Score
Get the complete analysis for BSP:OFSA3
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
